Scientists have been able to overcome chemotherapy resistance with low doses of adjuvant

US, WASHINGTON (ORDO NEWS) — An international research team led by scientists from the University of Queensland has found that chemotherapy resistance in one of the subtypes of ovarian cancer can be overcome by using low doses of a drug that slows cell growth. An article about this is published in Cancers.

In a preclinical study, they found that very low doses of 2-deoxy-D-glucose can be used to significantly increase the effectiveness of the chemo preparation carboplatin, usually used in the treatment of ovarian carcinoma. The data were obtained in laboratory modeling of treatment on cells taken from tissue samples of patients with clear cell ovarian cancer.

This type of malignant tumor is associated with poor prognosis and resistance to chemotherapy. Such carcinoma due to rapid development and aggressiveness, coupled with an erased picture of symptoms, is often detected only in the last stages. However, even when detected in the early stages and timely initiation of therapy, only about half of the patients show five-year survival after diagnosis. If belatedly detected, less than five percent succeed.

According to Professor John Hooper of the Institute for Translational Research (TRI) in Brisbane, their work provides the rationale for a clinical trial in humans that will help evaluate the benefits of using a low dose of 2-deoxy-D-glucose in treating patients with this type of cancer.

“The key conclusion of our study was that low levels of 2-deoxy-D-glucose significantly improved the effectiveness of carboplatin compared to preclinical models of this ovarian cancer,” the professor says. “Previously, this drug was tested for other forms of cancer, but we were able to use a 10-fold lower dose than previously reported, so it is safer for patients and less likely to cause side effects.”

The team hopes to begin trials of combination patient care over the next 12 months. It became known that scientists managed to get a grant from the National Organization for Clinical Trials of Gynecological Cancer in Australia and New Zealand – ANZGOG. It will be used for clinical tests and to study the prospects of such a treatment method.


Our Standards, Terms of Use: Standard Terms And Conditions.

Contact us: [email protected]